$0.66+0.02 (+3.36%)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
Matinas BioPharma Holdings, Inc. in the Healthcare sector is trading at $0.66 with a market capitalization of $5M. The stock is currently near its 52-week low of $0.48, remaining 25.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$1.94Mβ | -$1.60Mβ | -$1.58Mβ | -$1.84Mβ | -$1.95M |
| Net Income | -$1.92Mβ | -$1.91Mβ | -$1.53Mβ | -$5.25Mβ | -$1.66M |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocry...